SetPoint Medical on Monday announced that it has appointed Terry Bevirt as vice president of clinical affairs. The Valencia biomedical company said Bevirt will oversee clinical programs as the company moves forward with development of bioelectronic therapy for inflammatory conditions such as Crohn’s disease. The company said Bevirt will be working closely with its new Chief Medical Officer David Chernoff who was appointed to the position in June. Prior to joining SetPoint, Bevirt worked as head of clinical operations at Armagen, a clinical stage biotechnology company in Calabasas. “SetPoint is pleased to welcome Terry, whose senior leadership expertise and successful history running pivotal clinical trials will be crucial to us as we conduct clinical trials with our new proprietary bioelectronic medicine device,” Chief Executive Anthony Arnold said in a statement. “Terry will work closely with team leaders that make up a capable clinical team and ideally position SetPoint to develop and execute our clinical strategy through commercialization.”
